The 2026 JAMA Summit Report on Obesity examines the biological, socioeconomic, and environmental drivers of the global obesity epidemic, which now affects more than one billion people. The authors suggest that GLP-1 receptor agonists may already be contributing to declining US obesity prevalence, but lasting progress requires healthier food environments, equitable healthcare access, reduced weight stigma, and personalized treatment strategies.